---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-013321"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T18:41:52.679687+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma appoints Fred Hassan to board; he invests $2M in company

## Summary
- Fred Hassan appointed to Board of Directors on April 20, 2023, increasing board to six members.
- Hassan invested $2 million in Cocrystal, purchasing 1,015,229 shares alongside director Phillip Frost.
- Hassan brings 40-year pharma industry experience, having served as CEO of Schering-Plough and Pharmacia.

## SEC filing metadata
- accession: 0001493152-23-013321
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315223013321/0001493152-23-013321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315223013321/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-013321
- JSON: https://secwatch.observer/filing/0001493152-23-013321.json
- Plain text: https://secwatch.observer/filing/0001493152-23-013321.txt

## Key facts
- Executive change
  Fred Hassan was appointed as director at Cocrystal Pharma, Inc..
  - Action: appointed
  - Role: director
  source text: On April 20, 2023, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) appointed Fred Hassan as a director, thereby increasing the number of directors to six.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315223013321/0001493152-23-013321-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.